Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
London; NICE; Feb. 8, 2023. 27 p.
No convencional
en Inglés
| BIGG - guías GRADE
| ID: biblio-1415732
Biblioteca responsable:
BR1.1
ABSTRACT
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. Commercial arrangement There is a commercial arrangement for nivolumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UKCommercialEnquiries@bms.com for details.
Texto completo:
Disponible
Colección:
Bases de datos temática
Base de datos:
BIGG - guías GRADE
Asunto principal:
Carcinoma de Células Escamosas de Esófago
/
Inmunoterapia
/
Metástasis de la Neoplasia
Tipo de estudio:
Guía de práctica clínica
Idioma:
Inglés
Año:
2023
Tipo del documento:
No convencional
